samedan logo
 
 
spacer
home > epc > winter 2001 > arm for the pharmaceutical industry - protecting pharmaceutical brands and the impact of the internet
PUBLICATIONS
European Pharmaceutical Contractor

Arm for the Pharmaceutical Industry - Protecting Pharmaceutical Brands and the Impact of the Internet

Intellectual property has always been vital to the pharmaceutical industry. The future earnings of new drugs are assessed on the basis that they will have very high profit margins because of their virtual monopoly on the market until the patent expires. But once the 20-year patent expires, pharmaceutical companies increasingly rely on their brands to sustain sales on their blockbusting drugs.

The growth of the Internet is further complicating this issue. Whilst it offers opportunities to develop brands in new ways online, it also harbours many dangers for companies, particularly in controversial industries such as pharmaceuticals.

Pharmaceutical companies have long held the view that patents equal profits. Their products require vast investment in research and development, as well as extensive and rigorous testing, before they reach the market. But, given the fact that once a drug is approved, a well-drafted patent gives a pharmaceutical company 20 years of uninterrupted monopoly in which to sell and market a drug, pharmaceutical giants have traditionally paid more attention to their patent portfolio than to their trade marks and brands. GlaxoSmithKline's ranitidine hydrochloride (Zantac) is a good case in point. Zantac is an anti-ulcer drug for which Glaxo obtained a patent. To get an idea of the potential value of the patent, this monopoly was worth approximately two to three million pounds in profits to Glaxo for every single day that it lasted.


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Clarke Graham, Partner at Marks & Clerk, London

Clarke Graham graduated with a degree in Law from the University of Sydney. He worked with a firm of patent and trade mark attorneys in Australia before moving to London, later joining Marks & Clerk where he became a Partner in 1988. He opened the firm's office in Alicante. He has worked closely with clients and their design and advertising consultants in creating and administering effective and enforceable trade mark portfolios.

Clarke is also a specialist in international trade mark searching, protection and enforcement. He teaches on the University of Alicante's Masters Degree course in Intellectual Property. He is also a member of both ECTA and INTA.

spacer
Clarke Graham
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

Computer Systems Validation in the Pharmaceutical Industry

21-22 April 2010, London, UK

Make sure that you and your company’s knowledge of issues within the CSV arena is the best,  attend SMi’s Computer Systems Validation in the Pharmaceutical Industry conference taking place in April next year. Discussing issues such as regulatory aspects to CSV - whether the current guidelines need expanding, reinterpreting or rewriting - CSV in an R&D context, the need for a risk-based approach to CSV and many more, this conference promises to be an unmissable event.
More info >>

 
News and Press Releases

Vetter Wins the Axia Award

Vetter, a leading provider of aseptic pre-filled injection systems, has been awarded the 2009 Axia Award for best customer relationship management. The prize was announced on 4th February. Conferred yearly by the global auditing and consulting firm Deloitte, the award is given to medium-sized companies from Baden-Wuerttemberg, Germany, for sustainable and successful management.
More info >>

 

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement